Aspirin use low among high-risk colorectal cancer group
A study found that people with Lynch syndrome rarely use aspirin for cancer prevention despite evidence suggesting it may lower risk. The CAPP2 trial previously showed a benefit in this group.
This matters for people with Lynch syndrome and those at high colorectal cancer risk; evidence comes from a prior trial.
- study
- acetylsalicylic acid can significantly reduce the long-term risk of colorectal cancer
- population
- People with Lynch syndrome
Taken from the source as published — check the details before acting on them.
Study population
The CAPP2 study focused on individuals with Lynch syndrome, a hereditary condition linked to higher colorectal cancer risk.
Aspirin and cancer risk
The trial showed that aspirin may reduce long-term colorectal cancer risk in this high-risk group, though its use remains uncommon.
Common questions
Who is at higher risk for colorectal cancer in this study?
People with Lynch syndrome, a hereditary condition, were found to have a significantly increased risk of colorectal cancer.
What did the CAPP2 study find about aspirin use?
The study found that aspirin may reduce long-term colorectal cancer risk in people with Lynch syndrome, though its use is rare in this group.
Sources
- Aspirin rarely used for colorectal cancer prevention MedicalXpress · medicalxpress.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
